Recordati to market Vitaros for Erectile Dysfunction in Europe and Africa- Apricus Bioscience

Recordati has announced the signature of an exclusive license agreement with Apricus Biosciences Inc., for the marketing and sales of Vitaros (alprostadil), an innovative topical product for the treatment of Erectile Dysfunction, in certain European countries including, among others, Spain, EU member countries in Central and Eastern Europe, Russia and the Commonwealth of Independent States (C.I.S.), Turkey and certain African countries. Vitaros is approved for the treatment of erectile dysfunction by a number of European health authorities and by Health Canada. Vitaros is a topically-applied cream formulation of alprostadil, a vasodilator, which directly increases blood flow to the penis, causing an erection. Alprostadil is an alternative to the PDE-5 inhibitors for difficult to treat patients, and Vitaros offers a patient-friendly form versus other alprostadil dosage forms.